The inpatient burden and comorbidities of pyoderma gangrenosum in adults in the United States

[1]  A. Garg,et al.  Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis. , 2020, Journal of the American Academy of Dermatology.

[2]  Y. Jiao,et al.  Takayasu arteritis with pyoderma gangrenosum: case reports and literature review , 2019, BMC Rheumatology.

[3]  A. Ortega‐Loayza,et al.  Pyoderma gangrenosum: a review with special emphasis on Latin America literature , 2019, Anais brasileiros de dermatologia.

[4]  W. Robinson,et al.  Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa , 2019, Science Translational Medicine.

[5]  M. Rustin,et al.  Pyoderma gangrenosum - a guide to diagnosis and management . , 2019, Clinical medicine.

[6]  B. Kaffenberger,et al.  The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey , 2018, Journal of the American Academy of Dermatology.

[7]  A. Mostaghimi,et al.  The validity of the diagnostic code for pyoderma gangrenosum in an electronic database , 2018, The British journal of dermatology.

[8]  G. Pellacani,et al.  Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study , 2018, International wound journal.

[9]  B. Kaffenberger,et al.  The Validity of Pyoderma Gangrenosum ICD9-CM Coding in Hospital Administrative Datasets. , 2018, Journal of the American Academy of Dermatology.

[10]  C. Baugh,et al.  Outcomes of Early Dermatology Consultation for Inpatients Diagnosed With Cellulitis , 2018, JAMA dermatology.

[11]  C. Nelson,et al.  The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum , 2018, JAMA dermatology.

[12]  Rosie Qin,et al.  Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts , 2018, JAMA dermatology.

[13]  D. Fivenson,et al.  Pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH) syndrome with recurrent vasculitis , 2017, JAAD case reports.

[14]  M. Augustin,et al.  Tricenter analysis of cofactors and comorbidity in patients with pyoderma gangrenosum , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[15]  J. Elfar,et al.  Pyoderma gangrenosum and inflammatory bowel disease: A cross-sectional inpatient socioeconomic study. , 2015, Journal of the American Academy of Dermatology.

[16]  A. Ortega‐Loayza,et al.  Pathophysiology of pyoderma gangrenosum (PG): an updated review. , 2015, Journal of the American Academy of Dermatology.

[17]  D. Wetter,et al.  Pyoderma gangrenosum associated with solid organ malignancies , 2015, International journal of dermatology.

[18]  J. Klode,et al.  Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients , 2013, Orphanet Journal of Rare Diseases.

[19]  K. Shinkai,et al.  Etiology and Management of Pyoderma Gangrenosum , 2012, American Journal of Clinical Dermatology.

[20]  A. Qureshi,et al.  Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients , 2011, The British journal of dermatology.

[21]  D. Liew,et al.  Pyoderma gangrenosum requiring inpatient management: A report of 26 cases with follow up , 2011, The Australasian journal of dermatology.

[22]  I. Williams,et al.  Colonic neutrophils in inflammatory bowel disease: double-edged swords of the innate immune system with protective and destructive capacity. , 2007, Gastroenterology.

[23]  D. Vidal,et al.  Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features , 2004, The Journal of dermatological treatment.

[24]  S. Salpeter,et al.  Association between pyoderma gangrenosum and psoriasis , 1996, The Lancet.

[25]  A. Mowat,et al.  Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. , 1971, The Journal of clinical investigation.

[26]  C. Fife,et al.  Wound Care Outcomes and Associated Cost Among Patients Treated in US Outpatient Wound Centers: Data From the US Wound Registry. , 2012, Wounds : a compendium of clinical research and practice.

[27]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .